Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01485978
Other study ID # EARLY_PRO-TECT_ALPORT
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 2012
Est. completion date March 2019

Study information

Verified date June 2020
Source Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase III, multi-centre, randomised, placebo-controlled, patient and investigator-blind study in paediatric patients with early stages of Alport syndrome to assess the safety and efficacy of the ACEi ramipril in slowing disease progression.

Alport syndrome stages that describe the extent of renal damage and loss of function are defined as:

- 0 Microhaematuria without microalbuminuria (usually at birth)

- I Microalbuminuria (30-300 mg albumin/gCrea)

- II Proteinuria >300 mg albumin/gCrea

- III > 25% decline of normal renal function (creatinine clearance)

- IV End stage renal failure (ESRF)

Eligible patients with Alport stages 0 and I will be randomly assigned at a 2:1 ratio to receive once daily ramipril or placebo. In addition, Alport stage II patients may be treated open Label. Eligible patients who, or whose parents/legal guardian refuse randomisation after eligibility is confirmed, and patients who have been treated with ramipril prior to the study, may be treated open-label with ramipril as per protocol. The total number of patients will not exceed 120, with the number of randomised patients not exceeding 60, and the number of patients treated open label from Day 1 of the study aimed to be approximately 60.

Randomised patients whose disease progresses to the next disease level during the 3 year treatment period will be unblinded, and open label ramipril treatment will be initiated and continued, respectively, depending on prior treatment randomisation.


Recruitment information / eligibility

Status Completed
Enrollment 66
Est. completion date March 2019
Est. primary completion date September 2018
Accepts healthy volunteers No
Gender All
Age group 24 Months to 18 Years
Eligibility Inclusion Criteria:

- Definitive diagnosis of Alport syndrome: Kidney biopsy (patient or affected relative/s), and/or mutation analysis (hemizygous X-chromosomal or homozygous autosomal-recessive) and assessment of criteria for clinical diagnosis (haematuria, positive family history regarding kidney diseases, ocular changes, labyrinthine hearing loss)

- Alport syndrome levels 0, I or II at screening (microhaematuria without microalbuminuria or microalbuminuria [30-300 mg albumin/gCrea]) or proteinuria >300 mg albumin/gCrea with GFR>80ml/min). Patients with Alport stage II are not subject to randomization but are treated opel label.

- Aged between =24 months and <18 years at screening

- Assent from patient and informed consent from parents/legal guardian

Exclusion Criteria:

- Uncertain diagnosis or variants of Alport syndrome such as a heterozygous carrier

- Alport syndrome levels III, or IV (albuminuria >300 mg/g Crea, creatinine clearance <60 mL/min, or end stage renal failure [ESRF])

- Known allergies or intolerances to ramipril or related compounds

- Known contraindication for ACEi-therapy

- Additional chronic renal, pulmonary or cardiac diseases

- Pregnancy and lactation

Study Design


Intervention

Drug:
Ramipril
Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.
placebo to ramipril
Oral application of placebo to ramipril, once daily with 1 to 6 mg per body surface area for 3 years or until disease progression.
Ramipril
Oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years as per protocol.

Locations

Country Name City State
Germany University Medical Center Goettingen Goettingen

Sponsors (3)

Lead Sponsor Collaborator
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH German Federal Ministry of Education and Research, University Medical Center Goettingen

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Gross O, Tönshoff B, Weber LT, Pape L, Latta K, Fehrenbach H, Lange-Sperandio B, Zappel H, Hoyer P, Staude H, König S, John U, Gellermann J, Hoppe B, Galiano M, Hoecker B, Ehren R, Lerch C, Kashtan CE, Harden M, Boeckhaus J, Friede T; German Pediatric Nep — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Time to next disease level Time to progression of Alport Syndrome to the next disease level within 3 years under ramipril treatment compared to placebo, for all randomised patients. within 3 years
Primary Incidence of Adverse Drug Events before progression Incidence of adverse drug events (ADEs, e.g., angioedema, acute renal failure, hyperkalaemia) under ramipril treatment before disease progression compared to placebo before disease progression, for all randomised patients. within 3 years
Secondary Albuminuria after three years Albuminuria after 3 years corrected for baseline albuminuria for patients randomised to receive ramipril compared to placebo. after 3 years
Secondary Adverse Drug Events over three years Incidence of ADEs (e.g., angioedema, acute renal failure, hyperkalaemia) during 3 years of treatment for patients randomised to receive ramipril compared to placebo. after 3 years
See also
  Status Clinical Trial Phase
Terminated NCT05056727 - A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia Phase 3
Withdrawn NCT01655186 - A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus Phase 2
Completed NCT03481686 - Therapeutic Education of Chronic Renal or Renal Transplant Patient in the Management of EPO Injections N/A
Active, not recruiting NCT03672110 - Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen Phase 3
Enrolling by invitation NCT02237534 - Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia Phase 4
Completed NCT02126293 - Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant Phase 3
Terminated NCT01533545 - Effect of Epinephrine on Systemic Absorption of Mepivacaine in Uremic Patients N/A
Completed NCT03280615 - Omega 3 Fatty Acids in Patients With Chronic Renal Disease Phase 3
Completed NCT04498156 - Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D)
Recruiting NCT04020328 - Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency Phase 4
Recruiting NCT06366529 - Explore New Magnetic Resonance Technology in Assessment of Renal Dysfunction
Active, not recruiting NCT04876963 - HOLT-ED: Holter-monitoring in End-stage Renal Disease
Completed NCT03836508 - Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis N/A
Completed NCT03250715 - Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure N/A
Completed NCT03577249 - Biological Effects of Citrate-buffered Solutions on Dialysis Efficiency and Systemic Inflammation Phase 2/Phase 3
Completed NCT01975818 - Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 Phase 2
Active, not recruiting NCT05766644 - App-based Education Program for CKD N/A
Active, not recruiting NCT02791880 - Acute Kidney Injury Genomics and Biomarkers in TAVR Study
Recruiting NCT02947750 - Neurovascular Transduction During Exercise in Chronic Kidney Disease Phase 2
Terminated NCT02286258 - Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR) Phase 1/Phase 2

External Links